Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Conditions: Stage II-IVB Operable HNSCC Oral Cavity; Hypopharynx; Oropharynx; Larynx Interventions: Drug: Durvalumab; Drug: durvalumab + tremelimumab Sponsor: Yonsei University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials